Showing results (31-40 of 39) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 22, 2016
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension studyRalf Gold, Douglas L Arnold, Amit Bar-Or, et al.Journal of Neurology|November 16, 2019
Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisAlejandra González-Duarte, John L Berk, Dianna Quan, et al.Journal of Neurology|February 8, 2020
Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosisAlejandra González-Duarte, John L Berk, Dianna Quan, et al.Kidney International Reports|March 8, 2022
Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1Sally A Hulton, Jaap W Groothoff, Yaacov Frishberg, et al.The New England Journal of Medicine|March 31, 2021
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1Sander F Garrelfs, Yaacov Frishberg, Sally A Hulton, et al.The Lancet. Neurology|November 19, 2020
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension studyDavid Adams, Michael Polydefkis, Alejandra González-Duarte, et al.The New England Journal of Medicine|June 11, 2020
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent PorphyriaManisha Balwani, Eliane Sardh, Paolo Ventura, et al.The New England Journal of Medicine|July 5, 2018
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDavid Adams, Alejandra Gonzalez-Duarte, William D O'Riordan, et al.The New England Journal of Medicine|October 27, 2023
Patisiran Treatment in Patients with Transthyretin Cardiac AmyloidosisMathew S Maurer, Parag Kale, Marianna Fontana, et al.Pageof 4